<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00040300</url>
  </required_header>
  <id_info>
    <org_study_id>CI-PSI-004-02-101</org_study_id>
    <nct_id>NCT00040300</nct_id>
  </id_info>
  <brief_title>A 14-Day Study of Racivir When Used in Combination in HIV-Infected Males</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmasset</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmasset</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate Racivir. The safety, most effective dosage, and how&#xD;
      the body reacts to Racivir will be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a 14-day study with a 21-day follow-up period. During the 14-days of active&#xD;
      study period, participants will receive Racivir once daily in combination with efavirenz and&#xD;
      stavudine. Following the administration of the first and last dose of study medication,&#xD;
      patients will remain in the clinic overnight. During the study there will be medical and&#xD;
      medication histories taken, physical examinations, vital sign measurements, EKGs, and routine&#xD;
      clinical laboratory tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date>December 2002</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>18</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Racivir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Subjects may be eligible to participate if they:&#xD;
&#xD;
          -  Are males with HIV infection with a positive HIV antibody test&#xD;
&#xD;
          -  Have an HIV-RNA copy number of ≥ 5000 copies/ml (Roche assay)&#xD;
&#xD;
          -  Have CD4+ cell counts ≥ 50 cells/ml&#xD;
&#xD;
          -  Are 18-45 years of age, inclusive&#xD;
&#xD;
          -  Have a body mass index (BMI) ≥ 18 kg/m2&#xD;
&#xD;
          -  Are antiretroviral nucleoside reverse transcriptase inhibitor-naive&#xD;
&#xD;
          -  Have read and understand the informed consent,and is able and willing to comply with&#xD;
             study procedures&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Subjects may not participate if they:&#xD;
&#xD;
          -  Have clinically significant ECG abnormalities&#xD;
&#xD;
          -  Have clinically significant abnormalities in any safety laboratory parameters&#xD;
&#xD;
          -  Have an ALT value ≥ 3xUNL&#xD;
&#xD;
          -  Have previously participated in this trial&#xD;
&#xD;
          -  Have participated in another trial of an investigational drug within the last 3 months&#xD;
             or are currently participating in another trial of an investigational drug&#xD;
&#xD;
          -  Have a history of chronic alcohol or drug abuse within the last 6 months&#xD;
&#xD;
          -  Have a positive urine drug screening&#xD;
&#xD;
          -  Have a positive alcohol breath test&#xD;
&#xD;
          -  Have any medical or psychiatric condition, which in the opinion of the investigator&#xD;
             would jeopardize or compromise the subject's ability to participate in this trial&#xD;
&#xD;
          -  Have a known hypersensitivity to any components of the trial medication or comparative&#xD;
             drugs as stated in this protocol&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>July 2005</verification_date>
  <study_first_submitted>June 24, 2002</study_first_submitted>
  <study_first_submitted_qc>June 24, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2002</study_first_posted>
  <last_update_submitted>July 18, 2005</last_update_submitted>
  <last_update_submitted_qc>July 18, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2005</last_update_posted>
  <keyword>treatment experienced</keyword>
  <keyword>HIV</keyword>
  <keyword>Phase I</keyword>
  <keyword>Combination Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Racivir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

